18.9 C
New York
Wednesday, June 17, 2026

Tag: population

Jersey College Offers Associate Degree for NJ Nursing Students With and Without Prior Licensure

Teterboro and Ewing campuses offer full ADN program. Next class starts August 17.
Teterboro and Ewing campuses offer full ADN program. Next class starts August 17.

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

Alpha Residential Wins NAIOP Pittsburgh Best Multifamily Project Award for Apex Newbury

Alpha Residential is the recipient of the NAIOP Pittsburgh Best Multifamily Project award for Apex Newbury, the newest multifamily project in South Fayette

VEON Closes USD 1.4 Billion Bond Offering, Refinancing 2027 Notes Ahead of Schedule

Dubai and New York, June 2, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), today announces the successful closing of a USD 1.4 billion dual-tranche senior unsecured notes offering (the “Offering”) by its subsidiary VEON Midco B.V. (the “Issuer”). The Offering refinances substantially all of VEON’s debt maturing in 2027 ahead of schedule and reflects sustained confidence in VEON’s digital operator transformation and AI1440 strategy.

WeRide, Uber and AVOMO Bring Robotaxis to Madrid

WeRide and Uber announced plans to launch Spain’s first commercial Robotaxi pilot in Madrid, marking their first joint entry into the European market.

Uxin Enters into Joint Venture Agreement with Shijiazhuang State-Owned Enterprise

BEIJING, June 2, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), a leading used car retailer in China, today announced a...

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

Ping An Launches “Ping An Home” Service Brand

Advancing Proactive Health Management to Meet Chinese Families' Demand for Healthy LongevityHONG KONG and SHANGHAI, June 2, 2026 /PRNewswire/ -- As population aging accelerates...

Ping An Launches “Ping An Home” Service Brand

Advancing Proactive Health Management to Meet Chinese Families' Demand for Healthy LongevityHONG KONG and SHANGHAI, June 2, 2026 /PRNewswire/ -- As population aging accelerates...

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

National Healthcare Properties Provides Business Updates

Growing SHOP Acquisition Pipeline
Addition to the Russell 2000 and 3000 Indexes
Presentation at Nareit’s REITweek 2026 Investor Conference

Global Water Resources Declares Monthly Dividend

PHOENIX, May 29, 2026 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share).

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and...

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPopulation